2020
DOI: 10.14283/jpad.2020.24
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The termination of many clinical trials of amyloid-targeting therapies for the treatment of Alzheimer’s disease (AD) has had a major impact on the AD clinical research enterprise. However, positive signals in recent studies have reinvigorated support for the amyloid hypothesis and amyloid-targeting strategies. In December 2019, the EU-US Clinical Trials on Alzheimer’s Disease (CTAD) Task Force met to share learnings from these studies in order to inform future trials and promote the development of effective AD… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
26
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 32 publications
(26 citation statements)
references
References 28 publications
(18 reference statements)
0
26
0
Order By: Relevance
“…Finally, the mild AD population enrolled may have been too far along in their disease process to respond to a BACE inhibitor treatment. A BACE inhibitor trial was terminated in the preclinical AD population due to findings of dose-related cognitive worsening and neuropsychiatric adverse events [ 31 ], though it has been hypothesized that a viable low dose BACE inhibition regimen could be identified in the future [ 32 ]. A number of other trials, such as the A4 study [ 33 ] or the AHEAD 3–45 Study (NCT04468659) are attempting to target the amyloid pathway with other mechanisms of action in preclinical AD.…”
Section: Discussionmentioning
confidence: 99%
“…Finally, the mild AD population enrolled may have been too far along in their disease process to respond to a BACE inhibitor treatment. A BACE inhibitor trial was terminated in the preclinical AD population due to findings of dose-related cognitive worsening and neuropsychiatric adverse events [ 31 ], though it has been hypothesized that a viable low dose BACE inhibition regimen could be identified in the future [ 32 ]. A number of other trials, such as the A4 study [ 33 ] or the AHEAD 3–45 Study (NCT04468659) are attempting to target the amyloid pathway with other mechanisms of action in preclinical AD.…”
Section: Discussionmentioning
confidence: 99%
“…Increasing evidence suggests that the oligomeric aggregates which form as intermediates during the Aβ deposition process, rather than mature fibrils, are the predominant species capable of inducing neuronal dysfunction [4][5][6][7]. Targeting the rates of formation or the physicochemical properties of Aβ oligomers, therefore, represents one of the most promising therapeutic approaches to the treatment of AD [8,9].…”
Section: Introductionmentioning
confidence: 99%
“…ICOPE Monitor) and blood biomarkers must allow us to diagnoses early AD in primary care and give access to new therapies for these subjects. Aducanumap is the first, but several other drugs are in development (17,18) and will likely become available shortly as well as other drugs with different targets. We must use the FDA decision as a challenge to be prepared and to move our practice to prevention and early diagnosis (19) for our old patients.…”
Section: New Hopementioning
confidence: 99%